Agronomics Limited is a principal investment firm specializing in investments in funds, equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the alternative proteins company with a focus on cellular agriculture, nascent industry of modern foods, biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Agronomics Limited was founded on May 3, 2011 and is based in Ramsey, Isle of Man.

Agronomics Limited

Agronomics focuses on investment opportunities within the field of cellular agriculture, providing shareholders with exposure to a portfolio of companies in this emerging sector. The company utilizes technologies like cell culturing and precision fermentation to manufacture agricultural products.

Agronomics

Agronomics Limited | 4,681 followers on LinkedIn. Venture Capital firm. Investors in cellular agriculture, including cell culture, fermentation and alternative proteins. | Agronomics is the leading listed venture capital firm with a focus on cellular agriculture.  The Company has established a portfolio of over 20 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals.

Chief Sustainability Officer at Standard Chartered Bank

Marisa Drew

Investing in the field of cellular agriculture

Anthony Chow, CFA

Principal at Agronomics

Laura Turner

Operations Analyst - Cellular Agriculture

Harriet F.

Fantastic news today that our portfolio company Clean Food Group , the pioneering UK-based bio-tech business has entered into a strategic partnership with leading cosmetics product development and manufacturer, THG LABS. The two companies will work together to create revolutionary new raw materials, starting with a low impact, high-performance oil, for use in beauty and personal care products. The collaboration will leverage the expertise of THG LABS Innovation and Research and Development teams alongside Clean Food Group’s industry-leading technology in delivering sustainable oils and fats solutions to the world's food and cosmetics manufacturers. Clean Food Group’s proprietary technology platform uses proven, scalable non-GMO yeast strains and fermentation technology and harnesses bread waste as its food source, to deliver sustainable alternatives to traditional oil and fat ingredients. Professor Chris Chuck, Technical Lead for Clean Food said: “We are delighted to be collaborating with THG LABS, as a leading innovator and full-service manufacturer in the cosmetics industry. With the help of THG LABS, we are excited to bring to market a range of science-led cosmetics and personal care products that put sustainability at their core."

A reminder that the team at Formo will be delivering its Capital Markets Day presentation this afternoon. The Agronomics' Capital Markets Investor Presentation Series comprises individual presentations from industry-leading companies in the cell culture and precision fermentation sector within the Agronomics portfolio. For each presentation, the portfolio company's management team will provide in-depth insights into the purpose, market demand, technical milestones, and growth strategy of the company, together with a Question & Answer session at the end of the presentation. The presentation will include the senior management team at Formo Bio GmbH ("Formo") on 26 September 2024 at 15:00 BST. Attendees are able to register for the event using the following link: https://lnkd.in/eaP7xkcj . After registering, attendees will receive a confirmation email containing information about joining the webinar. Formo is an innovative European fermentation startup that is redefining the future of cheese. Founded in 2019, with locations in Berlin and Frankfurt, Formo develops animal-free alternatives that combine taste and sustainability. Using state-of-the-art fermentation technology, Formo creates cheese alternatives that taste great and contribute positively to the environment. Learn more at https://formo.bio/ . Formo recently announced that it has successfully raised US$ 61 million in its Series B funding round which will help the company achieve key milestones, including international expansion, diversifying the product range, driving revenue growth and achieving net profitability by 2027. Formo will also invest in its technology platform to accelerate the commercialisation of animal-free casein products, which will expand the portfolio to include hard cheeses, opening further opportunities in the market.

Agronomics is pleased to announce that it will be hosting the fourth presentation in its Capital Markets portfolio series. The Agronomics' Capital Markets Investor Presentation Series comprises individual presentations from industry-leading companies in the cell culture and precision fermentation sector within the Agronomics portfolio. For each presentation, the portfolio company's management team will provide in-depth insights into the purpose, market demand, technical milestones, and growth strategy of the company, together with a Question & Answer session at the end of the presentation. The presentation will include the senior management team at Formo Bio GmbH ("Formo") on 26 September 2024 at 15:00 BST. Attendees are able to register for the event using the following link: https://lnkd.in/eaP7xkcj . After registering, attendees will receive a confirmation email containing information about joining the webinar. Formo is an innovative European fermentation startup that is redefining the future of cheese. Founded in 2019, with locations in Berlin and Frankfurt, Formo develops animal-free alternatives that combine taste and sustainability. Using state-of-the-art fermentation technology, Formo creates cheese alternatives that taste great and contribute positively to the environment. Formo recently announced that it has successfully raised US$ 61 million in its Series B funding round which will help the company achieve key milestones, including international expansion, diversifying the product range, driving revenue growth and achieving net profitability by 2027. Formo will also invest in its technology platform to accelerate the commercialisation of animal-free casein products, which will expand the portfolio to include hard cheeses, opening further opportunities in the market. https://lnkd.in/eJKi-nua

We're excited to announce that our portfolio company, Solar Foods , has officially commenced trading on the Nasdaq First North Growth Market Finland! 🚀 This is a significant milestone for the company and a big step towards the enactment of its global growth strategy. A huge congratulations to the entire Solar Foods team, led by Pasi Vainikka and Ilkka Saura . We're excited to see what comes next! 🎉 #Agronomics #SolarFoods #FutureofFood #SustainableFood

We are excited to announce that our portfolio company, Formo , has secured EUR 50 million in Series B funding! 🎉 Formo is an innovative European fermentation startup developing animal-free cheese that combines great taste and sustainability. 🌍 This investment will allow Formo to enter the next stage of growth including international expansion and revenue growth as well as accelerating the commercialisation of animal-free casein products which will expand the product portfolio to include hard cheeses. In addition to the close of the round, Formo's first two products Frischhain and Camembritz, are now available at over 2000 REWE, BILLA and METRO stores across Germany and Austria. A huge congratulations to Raffael Wohlgensinger , Roman Plewka and the rest of the Formo team! #ANIC #Agronomics #FutureofFood

The Agronomics H2 newsletter is out today! This edition looks at the significant technical, commercial and financial progress made throughout the portfolio, with a number of companies continuing to demonstrate notable progress and achieving multiple new financings. You can read the full newsletter here: https://lnkd.in/enQjWYSm

We are delighted to announce that our portfolio company Galy has closed an oversubscribed $33 million Series B financing round. Founded in 2019 with a mission to find ethical and sustainable agricultural solutions, “GALY Cotton” is the company’s first product targeting conventional cotton practices. “GALY Cotton” is a new material that fully replicates traditional cotton in quality, retaining its exact attributes because it originates from an actual plant, all while offering ESG benefits, customizable quality and a clear roadmap to reach cost parity The funds from the round will primarily fuel the expansion of GALY’s research and development on its innovative cellular agriculture platform and its flagship product, “GALY Cotton,” which uses 99% less water and 97% less land than traditional cotton while emitting 77% less CO2, as it advances towards pre-industrial quality and scale. GALY has also secured millions of dollars in proof-of-concept agreements with top industry players and a 10-year, $50 million offtake agreement with Suzuran Medical, a Japanese medical supplies manufacturer, for the sourcing of "GALY Cotton.” Today's announcement is another one of the Agronomics portfolio company which has continued to demonstrate notable progress this quarter, achieving multiple new financings. You can read more in the Bloomberg piece to find out more here: https://lnkd.in/eej9R7pH

Our co-founder Anthony Chow, CFA spoke with Sifted about the current attitudes towards the cellular agriculture industry by Governments across Europe: “There's this perverse situation where Europe is so much more forward-thinking than most of the US when it comes to climate change and challenges around sustainability. The food system is one of the biggest burdens from greenhouse gas emissions and deforestation — but Europe is completely anti-application of biotechnology to food production. “There is proof that you can get products approved in Singapore and in the US — there is no evidence that you can in Europe. So why would you bear that additional risk?” Read the full piece at: https://lnkd.in/eayEb_RD

Our founder Jim Mellon spoke to the Sunday Times to discuss how, despite a difficult fundraising environment, many leading companies across the cellular agriculture industry are closing successful funding rounds: "London-listed Agronomics, an investment company specialising in “cellular agriculture”, has participated in six of the seven largest financings in the sector in the past year. “People are still raising money, if you’ve got a good enough story,” Jim Mellon said. Mellon pointed to Mosa Meat, a Dutch company set up by the industry’s founding father, Mark Post, who created the first lab-grown burger in 2013. It raised €40 million (£34 million) in April. Prolific Machines, a California start-up pioneering a technology that uses light to stimulate cell growth, raised $55 million in June. Agronomics’ portfolio of stakes in private companies should give it a market value of 18p per share, but that price has plunged to 5.5p; its shares stood at 28p three years ago. “The discount is absolutely vast. I can’t explain it,” Mellon said. “Having been around for a very long time in this business, I think that ultimately — as there are exits and companies are acquired for their intellectual property and so forth — the cycle will turn again.”

A great piece in City AM today on the back of Meatly 's historic achievement of receiving regulatory approval to sell its cultivated chicken for pet food in the UK. The piece looks at the growing role of investment companies like Agronomics in supporting private companies or smaller quoted companies to help finance innovation and drive growth. Speaking to City AM, Co-founder of Agronomics, Anthony Chow, CFA , said: "Innovation requires capital and one of the major conduits of capital to entrepreneurs in the UK is investment companies like Agronomics. "This model isn’t conventional in the US, but in the UK, it provides a mechanism by which non-institutional investors can gain exposure to industries of the future and invest in several industry-leading companies." Read the full piece here: https://lnkd.in/eBgnX6t9

	Jun '14	Jun '15	Jun '16	Jun '17	Jun '18	Jun '19	Jun '20	Jun '21	Jun '22	Jun '23
cost and expenses	621.33K -	451.94K 27.26%	224.59K 50.30%	227.35K 1.23%	192.76K 15.21%	224.92K 16.68%	720.60K 220.38%	9.69M 1,244.90%	4.92M 49.21%	5.14M 4.39%
cost of revenue								-10.41M -
depreciation and amortization	-2.10M -	340.61K 116.25%	627.68K 84.28%	-360.68K 157.46%	70.55K 119.56%	152.02K 115.49%	-1.93M 1,368.38%	-30.10M 1,461.33%	-22.44M 25.45%	-59.41M 164.72%
ebitda	-715.13K -	-261.16K 63.48%	93.28K 135.72%	-407.68K 537.05%	-157.53K 61.36%	-148.92K 5.47%	-1.38M 824.62%	-20.36M 1,378.70%	-11.35M 44.27%	-34.84M 207.07%
eps	0.04 -	-0.02 149.75%	-0.02 13.30%	-0.00 93.04%	-0.01 468.75%	-0.01 30.77%	0.01 155.46%	-0.02 348.48%	0.01 141.46%	0 100%
eps diluted	0.04 -	-0.02 149.75%	-0.02 13.30%	-0.00 93.04%	-0.01 468.75%	-0.01 30.77%	0.01 155.46%	-0.01 246.97%	0.01 167.01%	0 100%
general and administrative expenses	600.95K -	434.56K 27.69%	209.89K 51.70%	218.13K 3.92%	191.23K 12.33%	199.91K 4.54%	615.75K 208.01%	8.08M 1,212.16%	5.68M 29.75%	3.98M 29.92%
gross profit	2.10M -					-11.56K -	1.28M 11,153.70%	10.67M 735.31%
income before tax	1.38M -	-601.65K 143.55%	-534.37K 11.18%	-37.03K 93.07%	-211.41K 470.90%	-288.92K 36.67%	611.73K 311.73%	1.02M 66.71%	8.36M 719.58%	22.37M 167.68%
income tax expense	14 -	-122 971.43%	-31 74.59%	-9.97K 32,070.97%	-16.67K 67.19%	-12.02K 27.90%	-60.56K 403.73%	8.72M 14,505.33%	2.40M 72.54%
interest expense	14 -					176 -	930 428.41%	1.16K 24.52%	344.02K 29,608.38%
interest income		122 -	31 74.59%	9.97K 32,070.97%	16.67K 67.19%	12.02K 27.90%	60.56K 403.73%	149.66K 147.13%	344.02K 129.88%	1.17M 241.11%
net income	1.38M -	-601.65K 143.55%	-534.37K 11.18%	-37.03K 93.07%	-211.41K 470.90%	-276.90K 30.98%	611.73K 320.92%	-7.70M 1,359.33%	5.96M 177.40%	22.37M 275.22%
operating expenses	621.33K -	451.94K 27.26%	224.59K 50.30%	227.35K 1.23%	192.76K 15.21%	224.92K 16.68%	720.60K 220.38%	9.69M 1,244.90%	4.92M 49.21%	5.14M 4.39%
operating income	1.38M -	-601.77K 143.56%	-534.40K 11.20%	-47.00K 91.20%	-228.08K 385.25%	-300.94K 31.95%	551.17K 283.15%	9.74M 1,667.76%	11.10M 13.90%	24.57M 121.42%
other expenses	20.38K -	12.25K 39.90%	14.70K 20.02%	9.22K 37.25%	1.53K 83.39%	25.00K 1,532.18%	104.86K 319.34%	1.61M 1,437.10%	-894.21K 155.48%
research and development expenses
revenue	2.10M -					-11.56K -	1.28M 11,153.70%	260.10K 79.64%
selling and marketing expenses		5.13K -						41.57K -	141.08K 239.39%	148.29K 5.11%
selling general and administrative expenses	600.95K -	439.69K 26.83%	209.89K 52.26%	218.13K 3.92%	191.23K 12.33%	199.91K 4.54%	615.75K 208.01%	8.08M 1,212.16%	5.82M 28.01%	4.13M 29.07%
total other income expenses net	-14 -	122 971.43%	31 74.59%	9.97K 32,070.97%	16.67K 67.19%	12.02K 27.90%	60.56K 403.73%	-8.72M 14,505.33%	-2.74M 68.59%	-2.20M 19.73%
weighted average shs out	33.86M -	29.64M 12.47%	23.20M 21.74%	23.20M 0%	23.20M 0%	23.20M 0%	92.15M 297.28%	468.46M 408.35%	877.49M 87.31%
weighted average shs out dil	33.86M -	29.64M 12.48%	23.20M 21.74%	23.20M 0%	23.20M 0%	23.20M 0%	92.15M 297.28%	796.65M 764.49%	914.68M 14.82%

IM:AGRONOMICS

Agronomics

Last Close

3.84

13/11 16:35

Market Cap

592.12K

Beta: -

Volume Today

3.17M

Avg: -

Preview